Predictive biomarkers in endometrial carcinomas: a review of their relevance in daily anatomic pathology.

Autor: Nagel, Janaína¹ (AUTHOR), Paschoalini, Rafael Bispo² (AUTHOR) rafael.paschoalini@rededor.com.br, Barreto, Patrícia Sodré Dias³ (AUTHOR), Credidio, Caroline Haydn² (AUTHOR), Paulino, Eduardo⁴ (AUTHOR), Del Pilar Estevez-Diz, Maria⁵ (AUTHOR)

Publikováno v: Surgical & Experimental Pathology. 11/10/2024, Vol. 7 Issue 1, p1-20. 20p.

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.

Autor: Polak SB; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands., Van Gool IC; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., von der Thüsen JH; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., van Paassen J; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands. J.van_Paassen@lumc.nl.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2020 Nov; Vol. 33 (11), pp. 2128-2138. Date of Electronic Publication: 2020 Jun 22.

Evaluation of the Accuracy of a Polymerase Chain Reaction--Based Assay for Polymerase Epsilon Mutation Detection in Endometrial Carcinoma.

Autor: Tingting Chen¹, Yang Li¹, Xiao Li^1,2,3, Yanyun Zhang⁴, Weiguo Lv^1,2,5, Xing Xie^1,2,5, Xiaofei Zhang⁶, Xinyu Wang^1,2,5 wangxy@zju.edu.cn

Publikováno v: Archives of Pathology & Laboratory Medicine. Aug2024, Vol. 148 Issue 8, p945-951. 7p.

p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.

Autor: Vaziri Fard E, Imboden S, Rau T, Epstein E, Petta TB, Walia S, Carlson JW

Publikováno v: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists [Int J Gynecol Pathol] 2024 Sep 01; Vol. 43 (5), pp. 515-526. Date of Electronic Publication: 2024 May 09.

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Autor: Temko D; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.; Centre for Maths and Physics in the Life Sciences and Experimental Biology (CoMPLEX), University College London, London, UK.; Department of Computer Science, University College London, London, UK., Van Gool IC; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Rayner E; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Glaire M; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Makino S; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Brown M; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Chegwidden L; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Palles C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Depreeuw J; KU Leuven (University of Leuven), University Hospitals Leuven, Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Leuven, Belgium.; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.; VIB Centre for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium., Beggs A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Stathopoulou C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Mason J; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Baker AM; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Williams M; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.; Department of Cell and Developmental Biology, University College London, London, UK., Cerundolo V; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Rei M; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Taylor JC; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Schuh A; Department of Oncology, University of Oxford, Oxford, UK., Ahmed A; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK., Amant F; Centre for Gynaecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lambrechts D; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.; VIB Centre for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium., Smit VT; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Graham TA; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Church DN; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Tomlinson I; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Publikováno v: The Journal of pathology [J Pathol] 2018 Jul; Vol. 245 (3), pp. 283-296. Date of Electronic Publication: 2018 Apr 30.